• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » How to Use Pramipexole

How to Use Pramipexole

February 10, 2020
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Pramipexole is a selective agonist at the dopamine D3 receptor, which is thought to regulate hedonic drive. It is FDA approved in Parkinson’s disease and restless legs syndrome, and has five randomized controlled trials in depression. In unipolar depression it worked as monotherapy or augmentation, and in bipolar depression it worked as augmentation of a mood stabilizer (Gauthier C et al, Clin Neuropharmacol 2017;40(6):264–267).

Pramipexole’s most common side effects are nausea, hypotension, and fatigue, which are reduced by titrating it slowly and giving the dose at night. Start with 0.125–0.25 mg qhs and raise by 0.25 mg every 5–7 days toward a target dose of 0.75–2 mg qhs. Pramipexole has a low risk of weight gain and sexual dysfunction.

Serious side effects are pathological gambling, hallucinations, and daytime somnolence. Pathological gambling is part of a spectrum of hedonic behaviors called hedonistic homeostatic dysregulation (HDD) that can include excessive masturbation, overspending on eBay, and gambling into severe debt. Aripiprazole, another D3 agonist, can also cause these problems. HDD usually occurs without manic symptoms, and it is more common when dopaminergics are used in Parkinson’s disease than when they are used in mood disorders (Cartoon J & Ramalingam J, Australas Psychiatry 2019;27(5):456–461).

Long-term pramipexole use has been associated with congestive heart failure, but that association did not hold up in controlled investigations. Early reports of melanoma on pramipexole have since been linked to Parkinson’s disease itself rather than the medication, and warnings of melanoma were removed from the prescribing information in 2018.
General Psychiatry
KEYWORDS depression parkinsons-disease pramipexole
www.thecarlatreport.com
Issue Date: February 10, 2020
SUBSCRIBE NOW
Table Of Contents
Highlights From This Issue
An Answer for Psychotic Depression
Nuedexta in Agitated Dementia
Inflammatory Biomarkers in Depression
How to Use Pramipexole
Polypharmacy in Schizophrenia
CME Post-Test - Inflammation and Depression, TCPR, February 2020
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.